9月28日,阿斯利康(AZN)宣布以20亿美元认购Summit Therapeutics(SMMT)的可转换优先股,并围绕后者自康方生物(09926)授权引进的PD-1/VEGF双抗依沃西达成临床合作安排。 消息公布后投资者反应积极。康方生物9月29日涨15.54%,收报106.3港元,成交额34.78亿港元,较前一交易日的7.31亿港元明显增加。 9月30日,公司股价继续上涨,收盘市值重新...
Source Link9月28日,阿斯利康(AZN)宣布以20亿美元认购Summit Therapeutics(SMMT)的可转换优先股,并围绕后者自康方生物(09926)授权引进的PD-1/VEGF双抗依沃西达成临床合作安排。 消息公布后投资者反应积极。康方生物9月29日涨15.54%,收报106.3港元,成交额34.78亿港元,较前一交易日的7.31亿港元明显增加。 9月30日,公司股价继续上涨,收盘市值重新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.